India · Delayed Price · Currency is INR Entero Healthcare Solutions Earnings Call Transcripts
Fiscal Year 2027
-
Q1 revenue grew 38.2% and EBITDA margin reached 5%, with gross-margin expansion and stronger returns. FY27 guidance is unchanged; the strategy emphasizes organic growth, MedTech expansion and selective capital deployment.
Fiscal Year 2026
-
FY26 like-for-like revenue grew 31.5%, with 4.0% EBITDA margin and stronger cash generation. FY27 guidance targets 23% revenue growth and 5% EBITDA margin, with organic execution and MedTech expansion central to the plan.
-
Q3 revenue grew 26% YoY, with 17.1% organic growth, higher margins and ₹49 crore operating cash flow. Focus now shifts to integrating acquisitions and meeting FY26 cash-flow and margin targets.
-
Q2 revenue rose 20.8% YoY and EBITDA margin reached 4.0%, while working-capital days improved to 63. FY26 guidance remains 30% growth and INR 100 crore-plus operating cash flow, with H2 acquisition closures and MedTech expansion central to delivery.
-
Q1 revenue grew 28% YoY and like-for-like growth was 31%, with EBITDA margin at 3.6%. FY26 targets remain 30% revenue growth, 4%+ EBITDA margin, positive operating cash flow and 60-day working capital.
Fiscal Year 2025
-
FY25 revenue grew 30% to ₹5,096 crore and PAT reached ₹107 crore, with Q4 EBITDA margin at 3.7%. FY26 targets exceed 30% revenue growth, 4% EBITDA margin and positive full-year operating cash flow.
-
Q3 FY25 revenue rose 37% YoY, with 17% organic growth, while EBITDA margin expanded to 3.7%. Growth plans rely on continued acquisitions and organic expansion; positive operating cash flow is targeted next year, excluding acquisition investment.